#AACR20 roundup: Tecen­triq/Xtan­di com­bo fails to show OS ben­e­fit, halt­ing Roche's PD-L1 push in­to prostate can­cer

For the first time in its 100-year-plus his­to­ry, the Amer­i­can As­so­ci­a­tion for Can­cer Re­search is host­ing its an­nu­al meet­ing com­plete­ly on­line. Here’s a glance at some of the ab­stracts — which dropped ear­ly Mon­day — mak­ing the rounds:

Roche con­ced­ed that Tecen­triq failed to help prostate can­cer pa­tients live longer when added to Xtan­di, Pfiz­er and Astel­las’ main­stay an­dro­gen re­cep­tor an­tag­o­nist. The Phase III study dubbed IM­bas­sador en­rolled 759 pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer who had been treat­ed with one pri­or line of chemother­a­py and had pro­gressed af­ter tak­ing an­dro­gen syn­the­sis in­hibitors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.